Liquid Biopsy Market Projected to Grow at a Steady Pace During 2022-2028

According to Stratview Research’s latest report, titled “Liquid Biopsy Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Opportunity: 2022-2028”, the Liquid Biopsy Market is segmented by Products & Services Type (Assay Kits, Instruments, and Services), by Application Type (Cancer {Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others} and Non-Cancer), by Clinical Application Type (Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Early Cancer Screening), by Circulating Biomarkers Type (Circulating Tumor Cells, Cell-Free DNA, Circulating Tumor DNA, Extracellular Vesicles, and Others), by Technology Type (Multi-Gene Parallel Analysis Using NGS and Single-Gene Analysis Using PCR Microarrays), by End-User Type (Reference Laboratories, Hospitals and Physician Laboratories, Academic & Research Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World). This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the Liquid Biopsy Market.

Market Insights
According to analysts, the liquid biopsy market was estimated at USD 2.4 billion in 2021 and is expected to grow at a CAGR of 18% during 2022-2028 to reach USD 7.64 billion in 2028.

What is a liquid biopsy?
A liquid biopsy is a minimally invasive medical procedure that involves analyzing a blood sample or other bodily fluids to detect and monitor various diseases, including cancer. Unlike traditional biopsies, which require invasive surgical procedures, liquid biopsies offer a non-invasive alternative that can be performed more frequently and with less risk to the patient. Liquid biopsies can detect various biomarkers, such as circulating tumour cells (CTCs), cell-free DNA (cfDNA), and exosomes, providing valuable information on the existence and progression of cancer and other diseases. Liquid biopsies have the potential to revolutionize cancer diagnosis and treatment, as they enable doctors to monitor patients more closely and make more informed decisions about their care.

COVID-19 IMPACT
The impact of the global pandemic Covid-19 was felt across all industries in every field. However, the liquid biopsy market managed to escape the pandemic with minimum damage. The liquid biopsy market witnessed a slight decline in the year 2020 during the pandemic and is likely to rebound at a healthy rate in the forecast period.

Market Dynamics
The liquid biopsy market is driven by several factors, including the increasing prevalence of cancer and other diseases, the need for non-invasive diagnostic methods, and the growing demand for personalized medicine. Here are some of the key drivers of the liquid biopsy market:
• Cancer Prevalence: The rising incidence of cancer is one of the main drivers of the liquid biopsy market. As cancer rates continue to increase, there is a growing need for non-invasive and accurate methods of diagnosing and monitoring the disease.
• Non-Invasive Diagnostic Methods: Liquid biopsy provides a non-invasive alternative to traditional tissue biopsies, which can be invasive and painful for patients. This is particularly important for patients with advanced cancer or other conditions that make traditional biopsies difficult or risky.
• Personalized Medicine: Liquid biopsy provides doctors with a wealth of information about a patient's disease, including the specific mutations and biomarkers that may be driving the disease. This information can help doctors tailor treatment plans to the individual patient, leading to better outcomes.
• Technological Advancements: Advances in liquid biopsy technology, including improvements in sensitivity and specificity, are driving the adoption of this approach in clinical practice.
• Research Funding: Increased funding for research into liquid biopsy is fuelling innovation in this field, leading to new technologies and applications that are driving market growth.

Research Methodology
This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s Liquid Biopsy Market realities and future market possibilities for the forecast period of 2021 to 2026. The report segments and analyses the market in the most detailed manner in order to provide a panoramic view of the market. The vital data provided in the report can play a vital role in assisting market participants and investors in identifying low-hanging fruits available in the market as well as developing growth strategies to accelerate their growth process.

Segments Analysis
The liquid biopsy market is segmented into cancer and non-cancer applications. Cancer application is further sub-segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, and others. The cancer segment is likely to grow significantly at an exponential CAGR, during the forecast period, largely due to the increasing number of cancer cases and increasing demand for liquid biopsy for diagnosis. In addition, the increasing number of research studies on liquid biopsy for cancer applications is further expected to drive the growth of the market during the forecast period.

The market is segmented as multi-gene parallel analysis using NGS and single-gene analysis using PCR microarrays. Between these two technology types, the single-gene analysis using the PCR microarrays segment is expected to be dominant in the market over the forecast period. The segment's growth can be attributed to the use of PCR, which is increasing due to its increasing use for various purposes, including detecting fungal infections, bacterial infections, gene mapping, and other genomic applications. PCR tests' quick and real-time diagnostic results are accurate, and they can guide targeted therapies for cancer treatment. PCR is rapidly gaining popularity and is expected to grow at a rapid pace in the coming years.

Reference laboratories are expected to be the dominant segment of the market during the forecast period.
The market is segmented as reference laboratories, hospitals and physician laboratories, academic & research centers, and others. The outsourcing of liquid biopsy tests to reference laboratories is expected to drive market growth over the forecast period.
Among these regions, Asia-Pacific is expected to be the fastest-growing region in the market during the forecast period.

In 2021, North America had the highest revenue share of over 50%. Due to higher investments and the existence of numerous biotechnology businesses developing tests in the U.S., this region dominates the most.
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the world. The region is distinguished by rising disposable income, increasing healthcare expenditure, growing awareness of liquid biopsy techniques, and rising adoption of advanced diagnostic techniques in hospitals, clinics, and diagnostic laboratories. The growing penetration of hospitals and diagnostic centers in the region is likely to bolster the growth of the market over the forecast period. North America and Europe are also expected to offer substantial growth opportunities during the forecast period.

The list of Key Players in the report are -
The market for Liquid Biopsy is gradually consolidating with major companies that are performing mergers & acquisitions to quickly gain the leading position and to tap the growing opportunities in this briskly expanding market. Some of the major key players in the Liquid Biopsy Market are listed below.
• Biocept Inc.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche Ltd.
• Guardant Health Inc.
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Read More: https://www.stratviewresearch.com/3302/liquid-biopsy-market.html

Report Features -
This market report includes the following features –
- Market structure: Overview, industry life cycle analysis, supply chain analysis.
- Market environment analysis: Growth drivers and constraints.
- Market trend and forecast analysis.
- Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, M&As etc.
- Attractive market segments and associated growth opportunities.
- Emerging trends.

Custom Research:
Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

About Stratview Research –
Stratview Research is a leading market research firm that offers wide range of services like syndicated market reports, consulting, sourcing intelligence, and customer research, etc. Stratview Research’s offerings include comprehensive market intelligence in the form of research reports, and consulting services. Our team which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 500 companies.